NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free ALXO Stock Alerts $14.04 +0.25 (+1.81%) (As of 09:59 AM ET) Add Compare Share Share Today's Range$13.82▼$14.1050-Day Range$10.72▼$17.5652-Week Range$3.94▼$17.83Volume7,075 shsAverage Volume444,263 shsMarket Capitalization$731.48 millionP/E RatioN/ADividend YieldN/APrice Target$18.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ALX Oncology alerts: Email Address ALX Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside34.1% Upside$18.83 Price TargetShort InterestHealthy11.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 8 Articles This WeekInsider TradingSelling Shares$1.44 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.89) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.52 out of 5 starsMedical Sector267th out of 918 stocksPharmaceutical Preparations Industry116th out of 421 stocks 3.4 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageALX Oncology has only been the subject of 3 research reports in the past 90 days.Read more about ALX Oncology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.46% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in ALX Oncology has recently decreased by 14.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 3.2 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ALX Oncology this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold 2,799.04% more of their company's stock than they have bought. Specifically, they have bought $49,764.00 in company stock and sold $1,442,680.00 in company stock.Percentage Held by Insiders33.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ALX Oncology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($2.89) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ALX Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About ALX Oncology Stock (NASDAQ:ALXO)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesMay 16, 2024 | insidertrades.comInsider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 12,000 Shares of StockMay 9, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $318,400.00 in StockMay 17, 2024 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Stock Price Down 3.8% on Insider SellingMay 16, 2024 | finance.yahoo.comInsider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells SharesMay 16, 2024 | americanbankingnews.comShort Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Decreases By 14.4%May 12, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)May 10, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...May 10, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024May 9, 2024 | globenewswire.comALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comALX Oncology Appoints Allison Dillon as Chief Business OfficerMay 3, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09MApril 30, 2024 | finance.yahoo.comALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerApril 24, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 20, 2024 | investing.comAlx Oncology's president & CSO sells $710k in stockApril 18, 2024 | seekingalpha.comALX Oncology: Trying To Justify The HypeApril 18, 2024 | seekingalpha.comENPH, OCUL and ITCI are among after hour moversApril 13, 2024 | uk.investing.comALX Oncology hold rating reiterated with steady stock target by StifelApril 11, 2024 | markets.businessinsider.comBuy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV AnalysisApril 9, 2024 | globenewswire.comALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)April 8, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Evorpacept Trial Results and Market PotentialApril 6, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Insider Sells SharesMarch 20, 2024 | investing.comAlx Oncology CEO buys $49.7k in company sharesMarch 17, 2024 | finance.yahoo.comALXO Apr 2024 7.000 putMarch 16, 2024 | finance.yahoo.comALXO Apr 2024 14.000 putSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/21/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Target$18.83 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+34.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.41% Return on Assets-72.16% Debt Debt-to-Equity Ratio0.06 Current Ratio5.21 Quick Ratio5.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book3.69Miscellaneous Outstanding Shares52,100,000Free Float34,699,000Market Cap$731.48 million OptionableOptionable Beta1.30 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 72)Executive Chairman Comp: $84kMr. Jason W. Lettmann (Age 47)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, President, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 62)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 56)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.Vice President of OperationsMs. Shelly Pinto (Age 47)Senior VP of Finance & Chief Accounting Officer Comp: $508.26kDr. Christopher Byrd J.D.Ph.D., General CounselDr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentDr. Lin Yeong-Liang M.D.M.S., Senior Vice President of Drug Safety & PharmacovigilanceMore ExecutivesKey CompetitorsLongboard PharmaceuticalsNASDAQ:LBPHDisc MedicineNASDAQ:IRONPraxis Precision MedicinesNASDAQ:PRAXEvolusNASDAQ:EOLSArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsRedmile Group LLCBought 667,245 shares on 5/16/2024Ownership: 8.304%California State Teachers Retirement SystemBought 18,360 shares on 5/16/2024Ownership: 0.044%Price T Rowe Associates Inc. MDSold 310,474 shares on 5/15/2024Ownership: 0.447%EntryPoint Capital LLCBought 2,847 shares on 5/14/2024Ownership: 0.005%CANADA LIFE ASSURANCE CoBought 2,379 shares on 5/14/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions ALXO Stock Analysis - Frequently Asked Questions Should I buy or sell ALX Oncology stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks. What is ALX Oncology's stock price target for 2024? 6 brokerages have issued 1 year price objectives for ALX Oncology's stock. Their ALXO share price targets range from $11.00 to $27.00. On average, they predict the company's share price to reach $18.83 in the next year. This suggests a possible upside of 34.1% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts. How have ALXO shares performed in 2024? ALX Oncology's stock was trading at $14.89 on January 1st, 2024. Since then, ALXO shares have decreased by 5.7% and is now trading at $14.04. View the best growth stocks for 2024 here. When is ALX Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ALXO earnings forecast. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09. What ETFs hold ALX Oncology's stock? ETFs with the largest weight of ALX Oncology (NASDAQ:ALXO) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Inspire Small/Mid Cap ETF (ISMD). What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did ALX Oncology IPO? ALX Oncology (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? ALX Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Redmile Group LLC (8.30%), Vanguard Group Inc. (3.13%), Price T Rowe Associates Inc. MD (0.45%), Los Angeles Capital Management LLC (0.20%), Swiss National Bank (0.09%) and Inspire Investing LLC (0.07%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALXO) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.